Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.71 |
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine SCHEMBL14031844 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL5505924 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12232219 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL977919 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12018226 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL1981701 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL3047091 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL3655059 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL6882489 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL13046076 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024152052-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | AREVA PHARMACEUTICALS INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230277575-A1 | Nucleoside Analogues to Inhibit the Main Protease of a Coronavirus | Institut de Recherche en Semiochimie et Ethologie Appliquee (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20110046142-A1 | ANTIBIOTIC COMPOUNDS | NORTHEASTERN UNIVERSITY (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046142-A1 | ANTIBIOTIC COMPOUNDS | NORTHEASTERN UNIVERSITY (US) | 2011-02-24 | — | — | US | disclosed |
| EP-1866324-B1 | PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CARDIFF PROTIDES LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009129094-A2 | COMPOSITIONS CONTAINING ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | MALLINCKRODT INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080027044-A1 | Prodrug antibiotic screens | NORTHEASTERN UNIVERSITY | 2008-01-31 | — | — | US | disclosed |
| US-20080027044-A1 | Prodrug antibiotic screens | NORTHEASTERN UNIVERSITY | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046142-A1 | ANTIBIOTIC COMPOUNDS | AADAC, SPOUT1, NRDC | LMNA 2276/4885NT5E 1487/4885HIF1A 2946/4885 |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | EIF2AK2, MAVS, IRF3 | LMNA 3366/4885NT5E 2725/4885HIF1A 1962/4885 |
| US-20230277575-A1 | Nucleoside Analogues to Inhibit the Main Protease of a Coronavirus | ACE, ACE2, METAP1 | LMNA 1454/4885NT5E 740/4885HIF1A 4355/4885 |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | LMNA 2993/4885NT5E 89/4885HIF1A 919/4885 |
| US-20080027044-A1 | Prodrug antibiotic screens | O60361, PGLS, GUSB | LMNA 4462/4885NT5E 133/4885HIF1A 3162/4885 |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | LMNA 4433/4885NT5E 4404/4885HIF1A 2909/4885 |
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | CD38, FLAD1, GART | LMNA 1522/4885NT5E 1122/4885HIF1A 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.